Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.
2.

Differences in primary cardiovascular disease prevention between the 2013 and 2016 cholesterol guidelines and impact of the 2017 hypertension guideline in the United States.

Egan BM, Li J, Davis RA, Fiscella KA, Tobin JN, Jones DW, Sinopoli A.

J Clin Hypertens (Greenwich). 2018 Jun;20(6):991-1000. doi: 10.1111/jch.13314. Epub 2018 May 18.

3.

Measure Accurately, Act Rapidly, and Partner With Patients (MAP) improves hypertension control in medically underserved patients: Care Coordination Institute and American Medical Association Hypertension Control Project Pilot Study results.

Hanlin RB, Asif IM, Wozniak G, Sutherland SE, Shah B, Yang J, Davis RA, Bryan ST, Rakotz M, Egan BM.

J Clin Hypertens (Greenwich). 2018 Jan;20(1):79-87. doi: 10.1111/jch.13141. Epub 2018 Jan 5.

4.

Cholesterol Control Among Uninsured Adults Did Not Improve From 2001-2004 to 2009-2012 as Disparities With Both Publicly and Privately Insured Adults Doubled.

Egan BM, Li J, Sarasua SM, Davis RA, Fiscella KA, Tobin JN, Jones DW, Sinopoli A.

J Am Heart Assoc. 2017 Nov 2;6(11). pii: e006105. doi: 10.1161/JAHA.117.006105.

5.

Opportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline-recommended statin therapy.

Sarasua SM, Li J, Hernandez GT, Ferdinand KC, Tobin JN, Fiscella KA, Jones DW, Sinopoli A, Egan BM.

J Clin Hypertens (Greenwich). 2017 Sep;19(9):850-860. doi: 10.1111/jch.13004. Epub 2017 May 7.

6.

Physical Activity and Hypertension: Knowing Is Not Enough; We Must Apply. Willing Is Not Enough; We Must Do-von Goethe.

Egan BM.

Hypertension. 2017 Mar;69(3):404-406. doi: 10.1161/HYPERTENSIONAHA.116.08508. Epub 2017 Jan 30. No abstract available.

PMID:
28137989
7.

Relationship between risk factor control and vascular events in the SAMMPRIS trial.

Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane B, Montgomery J, Chimowitz MI.

Neurology. 2017 Jan 24;88(4):379-385. doi: 10.1212/WNL.0000000000003534. Epub 2016 Dec 21.

8.

Low Blood Pressure Is Associated With Greater Risk for Cardiovascular Events in Treated Adults With and Without Apparent Treatment-Resistant Hypertension.

Egan BM, Kai B, Wagner CS, Fleming DO, Henderson JH, Chandler AH, Sinopoli A.

J Clin Hypertens (Greenwich). 2017 Mar;19(3):241-249. doi: 10.1111/jch.12904. Epub 2016 Oct 21.

9.

2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals.

Egan BM, Li J, White K, Fleming DO, Connell K, Hernandez GT, Jones DW, Ferdinand KC, Sinopoli A.

J Am Heart Assoc. 2016 Aug 19;5(8). pii: e003558. doi: 10.1161/JAHA.116.003558. Erratum in: J Am Heart Assoc. 2016 Oct 18;5(10 ):.

10.

Visceral adiposity syndrome.

Lopes HF, Corrêa-Giannella ML, Consolim-Colombo FM, Egan BM.

Diabetol Metab Syndr. 2016 Jul 19;8:40. doi: 10.1186/s13098-016-0156-2. eCollection 2016. Review.

11.

Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.

Egan BM, Li J, Wagner CS.

Hypertension. 2016 Aug;68(2):318-23. doi: 10.1161/HYPERTENSIONAHA.116.07575. Epub 2016 Jun 27.

PMID:
27354422
12.

Aldosterone Antagonists or Renin-Guided Therapy for Treatment-Resistant Hypertension: A Comparative Effectiveness Pilot Study in Primary Care.

Egan BM, Laken MA, Sutherland SE, Qanungo S, Fleming DO, Cook AG, Hester WH, Jones KW, Jebaily GC, Valainis GT, Way CF, Wright MB, Davis RA.

Am J Hypertens. 2016 Aug;29(8):976-83. doi: 10.1093/ajh/hpw016. Epub 2016 Apr 13.

13.

Prevalence of Nutrition and Health-Related Claims on Pre-Packaged Foods: A Five-Country Study in Europe.

Hieke S, Kuljanic N, Pravst I, Miklavec K, Kaur A, Brown KA, Egan BM, Pfeifer K, Gracia A, Rayner M.

Nutrients. 2016 Mar 3;8(3):137. doi: 10.3390/nu8030137.

14.

Abnormalities of Anthropometric, Hemodynamic, and Autonomic Variables in Offspring of Hypertensive Parents.

Motta JM, Lemos TM, Consolim-Colombo FM, Moyses RM, Gusmão MA, Egan BM, Lopes HF.

J Clin Hypertens (Greenwich). 2016 Sep;18(9):942-8. doi: 10.1111/jch.12800. Epub 2016 Mar 2.

15.

Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension.

Egan BM, Kai B, Wagner CS, Henderson JH, Chandler AH, Sinopoli A.

J Clin Hypertens (Greenwich). 2016 Aug;18(8):817-24. doi: 10.1111/jch.12773. Epub 2016 Feb 9.

16.

Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network.

Egan BM, Sutherland SE, Childers WF, Dahlheimer RM, Helmrich GA, Lapeyrolerie DA, Markle N, Murphy DW, Simmons L, Davis RA, Tilkemeier P, Sinopoli A.

Ther Adv Cardiovasc Dis. 2016 Apr;10(2):56-66. doi: 10.1177/1753944715624854. Epub 2016 Jan 4.

17.

Weight Loss Pharmacotherapy: Brief Summary of the Clinical Literature and Comments on Racial Differences.

Egan BM, White K.

Ethn Dis. 2015 Nov 5;25(4):511-4. doi: 10.18865/ed.25.4.511. Review.

18.

Treatment Resistant Hypertension.

Egan BM.

Ethn Dis. 2015 Nov 5;25(4):495-8. doi: 10.18865/ed.25.4.495. Review.

19.

Social and Medical Determinants of Cardiometabolic Health: The Big Picture.

Puckrein GA, Egan BM, Howard G.

Ethn Dis. 2015 Nov 5;25(4):521-4. doi: 10.18865/ed.25.4.521. Review.

20.

Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community-Based Practice Registry.

Egan BM, Li J, Fleming DO, White K, Connell K, Davis RA, Sinopoli A.

J Clin Hypertens (Greenwich). 2016 Jul;18(7):663-71. doi: 10.1111/jch.12727. Epub 2015 Nov 26.

21.

The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome.

Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM.

J Am Coll Cardiol. 2015 Sep 1;66(9):1050-67. doi: 10.1016/j.jacc.2015.06.1328. Review.

22.

The importance of masked hypertension in adults with prehypertension.

Egan BM, Stevens-Fabry S.

Nat Rev Cardiol. 2015 Aug;12(8):497. doi: 10.1038/nrcardio.2015.100. Epub 2015 Jul 7. No abstract available.

PMID:
26149482
23.

Elijah Saunders in Memoriam.

Egan BM.

J Clin Hypertens (Greenwich). 2015 Jun;17(6):415-7. doi: 10.1111/jch.12587. Epub 2015 Jun 11. No abstract available.

24.

Hypertension in african americans aged 60 to 79 years: statement from the international society of hypertension in blacks.

Egan BM, Bland VJ, Brown AL, Ferdinand KC, Hernandez GT, Jamerson KA, Johnson WR, Kountz DS, Li J, Osei K, Reed JW, Saunders E.

J Clin Hypertens (Greenwich). 2015 Apr;17(4):252-9. doi: 10.1111/jch.12511. Epub 2015 Mar 10.

25.

Prehypertension--prevalence, health risks, and management strategies.

Egan BM, Stevens-Fabry S.

Nat Rev Cardiol. 2015 May;12(5):289-300. doi: 10.1038/nrcardio.2015.17. Epub 2015 Feb 17. Review.

PMID:
25687779
26.

Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort.

Nietert PJ, Shaftman SR, Silver RM, Wolf BJ, Egan BM, Hunt KJ, Smith EA.

Clin Epidemiol. 2015 Feb 3;7:161-8. doi: 10.2147/CLEP.S75482. eCollection 2015.

27.

Chaos to complexity: leveling the playing field for measuring value in primary care.

Moran WP, Zhang J, Gebregziabher M, Brownfield EL, Davis KS, Schreiner AD, Egan BM, Greenberg RS, Kyle TR 3rd, Marsden JE, Ball SJ, Mauldin PD.

J Eval Clin Pract. 2017 Apr;23(2):430-438. doi: 10.1111/jep.12298. Epub 2015 Feb 4.

PMID:
25652744
28.

Influence of acute hyperlipidemia to adipocyte-derived hormones in lean normotensive and subjects with metabolic syndrome.

Lopes HF, Klein RL, Garvey WT, Goodfriend T, Egan BM.

Diabetol Metab Syndr. 2014 Dec 2;6(1):132. doi: 10.1186/1758-5996-6-132. eCollection 2014.

29.
30.

Effectiveness of a tailored behavioral intervention to improve hypertension control.

Egan BM.

Hypertension. 2015 Feb;65(2):273-5. doi: 10.1161/HYPERTENSIONAHA.114.04650. Epub 2014 Nov 17. No abstract available.

31.

Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals.

Egan BM, Li J, Hutchison FN, Ferdinand KC.

Circulation. 2014 Nov 4;130(19):1692-9. doi: 10.1161/CIRCULATIONAHA.114.010676. Epub 2014 Oct 20.

32.

Antihypertensive medication persistence 1-year post-stroke hospitalization.

Boan AD, Egan BM, Bachman DL, Adams RJ, Feng WW, Jauch EC, Ovbiagele B, Lackland DT.

J Clin Hypertens (Greenwich). 2014 Dec;16(12):869-74. doi: 10.1111/jch.12424. Epub 2014 Oct 13.

33.

Blood Pressure, Heart Rate, and CNS Stimulant Medication Use in Children with and without ADHD: Analysis of NHANES Data.

Hailpern SM, Egan BM, Lewis KD, Wagner C, Shattat GF, Al Qaoud DI, Shatat IF.

Front Pediatr. 2014 Sep 19;2:100. doi: 10.3389/fped.2014.00100. eCollection 2014.

34.

Relationship between chronic kidney disease and metabolic syndrome: current perspectives.

Nashar K, Egan BM.

Diabetes Metab Syndr Obes. 2014 Sep 18;7:421-35. doi: 10.2147/DMSO.S45183. eCollection 2014. Review.

35.

The growing gap in hypertension control between insured and uninsured adults: National Health and Nutrition Examination Survey 1988 to 2010.

Egan BM, Li J, Small J, Nietert PJ, Sinopoli A.

Hypertension. 2014 Nov;64(5):997-1004. doi: 10.1161/HYPERTENSIONAHA.114.04276. Epub 2014 Sep 2.

36.

Opportunities for multidisciplinary ASH clinical hypertension specialists in an era of population health and accountable care: ASH leadership message.

Egan BM.

J Am Soc Hypertens. 2014 Jul;8(7):451-6. doi: 10.1016/j.jash.2014.05.016. Epub 2014 Jun 28.

PMID:
25064766
37.

Role of aldosterone blockade in resistant hypertension.

Egan BM, Li J.

Semin Nephrol. 2014 May;34(3):273-84. doi: 10.1016/j.semnephrol.2014.04.004. Epub 2014 Apr 28. Review.

PMID:
25016399
38.

Increasing capacity for quality improvement in underresourced primary care settings.

Hudson SM, Hiott DB, Cole J, Davis R, Egan BM, Laken MA.

Qual Manag Health Care. 2014 Jul-Sep;23(3):155-62. doi: 10.1097/QMH.0000000000000031.

PMID:
24978164
39.

Diabetes and age-related demographic differences in risk factor control.

Egan BM, Li J, Wolfman TE, Sinopoli A.

J Am Soc Hypertens. 2014 Jun;8(6):394-404. doi: 10.1016/j.jash.2014.03.323. Epub 2014 May 11.

40.

Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010.

Egan BM, Li J, Shatat IF, Fuller JM, Sinopoli A.

Circulation. 2014 May 20;129(20):2052-61. doi: 10.1161/CIRCULATIONAHA.113.007699. Epub 2014 Apr 14.

41.

Formation of community-based hypertension practice networks: success, obstacles, and lessons learned.

Dart RA, Egan BM.

J Clin Hypertens (Greenwich). 2014 Jun;16(6):393-7. doi: 10.1111/jch.12310. Epub 2014 Mar 26.

42.

Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity.

Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA.

Hypertension. 2014 Mar;63(3):e17-8. No abstract available.

43.

The impact of metabolic syndrome on metabolic, pro-inflammatory and prothrombotic markers according to the presence of high blood pressure criterion.

Gil JS, Drager LF, Guerra-Riccio GM, Mostarda C, Irigoyen MC, Costa-Hong V, Bortolotto LA, Egan BM, Lopes HF.

Clinics (Sao Paulo). 2013 Dec;68(12):1495-501. doi: 10.6061/clinics/2013(12)04.

44.

Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives.

Bhagatwala J, Harris RA, Parikh SJ, Zhu H, Huang Y, Kotak I, Seigler N, Pierce GL, Egan BM, Dong Y.

J Clin Hypertens (Greenwich). 2014 Jan;16(1):47-53. doi: 10.1111/jch.12218. Epub 2013 Oct 31.

45.

In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension.

Julius S, Egan BM, Kaciroti NA, Nesbitt SD, Chen AK; TROPHY investigators.

J Hypertens. 2014 Feb;32(2):251-9. doi: 10.1097/HJH.0000000000000032.

PMID:
24275841
46.

Pre-hypertension: rationale for pharmacotherapy.

Egan BM, Laken MA.

Curr Hypertens Rep. 2013 Dec;15(6):669-75. doi: 10.1007/s11906-013-0387-7. Review.

PMID:
24142744
47.

Prediction of incident hypertension. Health implications of data mining in the 'Big Data' era.

Egan BM.

J Hypertens. 2013 Nov;31(11):2123-4. doi: 10.1097/HJH.0b013e328365b932. No abstract available.

PMID:
24096252
48.

Blood pressure reclassification in adolescents based on repeat clinic blood pressure measurements.

Becton LJ, Egan BM, Hailpern SM, Shatat IF.

J Clin Hypertens (Greenwich). 2013 Oct;15(10):717-22. doi: 10.1111/jch.12168. Epub 2013 Jul 16.

49.

Collectrin, an X-linked, angiotensin converting enzyme 2 homolog, causes hypertension in a rat strain through gene-gene and gene-environment interactions: relevance to human hypertension.

Egan BM.

Circulation. 2013 Oct 15;128(16):1727-8. doi: 10.1161/CIRCULATIONAHA.113.005695. Epub 2013 Sep 18. No abstract available.

PMID:
24048199
50.

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA.

Hypertension. 2013 Oct;62(4):691-7. doi: 10.1161/HYPERTENSIONAHA.113.01448. Epub 2013 Aug 5.

Supplemental Content

Support Center